PRECIGEN, INC. Shareholders' Equity
PRECIGEN, INC. (PGEN) had Shareholders' Equity of $43.58 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-04
- 2026-06-30: Stockholders' Equity Attributable to Parent $43.58M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $20.23M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $20.91M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $41.87M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $43.58M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $20.23M 10-Q · filed 2026-08-04 | |
| 2025-12-31 | $20.91M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $41.87M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$36.78M 10-Q · filed 2026-08-04 | |
| 2025-03-31 | -$14.06M 10-Q · filed 2026-08-04 | |
| 2024-12-31 | $38.51M 10-Q · filed 2026-08-04 | |
| 2024-09-30 | $55.38M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $43.17M 10-Q · filed 2025-11-13 | |
| 2024-03-31 | $97.02M 10-Q · filed 2025-08-12 | |
| 2023-12-31 | $118.50M 10-K · filed 2026-03-25 | |
| 2023-09-30 | $147.68M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $166.21M 10-Q · filed 2024-11-14 | |
| 2023-03-31 | $184.13M 10-Q · filed 2024-08-14 | |
| 2022-12-31 | $126.26M 10-K · filed 2026-03-25 | |
| 2022-09-30 | $142.53M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $55.65M 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $73.84M 10-Q · filed 2023-08-09 | |
| 2021-12-31 | $107.35M 10-K · filed 2025-03-19 | |
| 2021-09-30 | $131.25M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $159.20M 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $174.79M 10-Q · filed 2022-08-08 | |
| 2020-12-31 | $67.17M 10-K · filed 2024-03-19 | |
| 2020-09-30 | $58.55M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $49.54M 10-Q · filed 2021-11-08 | |
| 2020-03-31 | $87.23M 10-Q · filed 2021-08-09 | |
| 2019-12-31 | $71.71M 10-K · filed 2023-03-06 | |
| 2019-09-30 | $228.42M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $279.22M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $313.03M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $362.86M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $539.40M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $549.75M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | $615.80M 10-Q/A · filed 2018-08-13 | $553.11M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $533.63M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $533.61M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $550.87M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $528.54M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $560.24M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $600.47M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $619.23M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $664.93M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $694.08M 10-K · filed 2017-03-01 | |
| 2015-09-30 | $718.29M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $474.83M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $640.67M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $384.76M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $358.36M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $373.25M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $415.90M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $366.72M 10-K · filed 2015-03-02 | |
| 2013-09-30 | $377.13M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | -$376.15M 10-Q/A · filed 2013-10-21 | |
| 2012-12-31 | -$321.55M 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |